Beta Bionics initiated with a Buy at Ladenburg

Ladenburg analyst Jeffrey Cohen initiated coverage of Beta Bionics (BBNX) with a Buy rating and $31 price target The medical device company offers the iLet Bionic Pancreas, which is the first FDA-cleared fully autonomous insulin delivery system, and has developed an AI-driven closed-loop algorithm that automatically adjusts insulin delivery based only on CGM data and the patient’s weight, the analyst tells investors. The diabetes market is valued at approximately $400B, yet insulin pump adoption remains low, adds the analyst, who bases the firm’s price target on its FY27 revenue estimate.